| pubmed-article:2037387 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0009402 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0031001 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2037387 | lifeskim:mentions | umls-concept:C0075172 | lld:lifeskim |
| pubmed-article:2037387 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2037387 | pubmed:dateCreated | 1991-7-1 | lld:pubmed |
| pubmed-article:2037387 | pubmed:abstractText | To evaluate the safety of on-line plasma perfusion over protein-A sepharose and the therapeutic advantage of combining plasma perfusion (PP) over protein-A sepharose with 5-fluorouracil (5-FU) chemotherapy in patients with metastatic colorectal carcinoma (MCRC), thirty patients were randomized after surgery of primary CRC to receive a combination of 5-FU and PP over protein-A sepharose (group A), or a combination of 5-FU and PP over sepharose (group B), or 5-FU alone (group C). Bi-weekly on-line PP over 200 ml protein-A sepharose gel (group A) or 200 ml sepharose gel (group B) were performed with a Cobe 2997 blood cell separator for a maximum of 19 treatments per patient. 5-FU was given at 1000 mg/m2/d on days 1-5 of a 4-weekly cycle until progression. PP was well tolerated and no severe or life-threatening toxicity was observed. Mild clinical side-effects consisted of fever and chills (36% in group A, 23% in group B). The most common biological effects of PP over protein-A sepharose were significant drops in IgG (66% of pre-PP values), CH50 and C3 (73% of pre-PP values) and a significant generation of C3a and C5a anaphylatoxins. Tumor response rates were 40% for group A, 0% for group B and 20% for group C. The median survival times tended to be longer in group A (17 months) than in group B (10 months) and in group C (9 months). This is the first randomized trial showing some therapeutic advantage in combining PP over protein-A sepharose with conventional chemotherapy in MCRC. | lld:pubmed |
| pubmed-article:2037387 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2037387 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2037387 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2037387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2037387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2037387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2037387 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2037387 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:2037387 | pubmed:issn | 0391-3988 | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:EbenAA | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:ArnaudJ PJP | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:FolleaGG | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:WieselM LML | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:FaradjiAA | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:GoetzJJ | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:BohbotAA | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:PiemontYY | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:LaustriatDD | lld:pubmed |
| pubmed-article:2037387 | pubmed:author | pubmed-author:DamonteJJ | lld:pubmed |
| pubmed-article:2037387 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2037387 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:2037387 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2037387 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2037387 | pubmed:pagination | 109-15 | lld:pubmed |
| pubmed-article:2037387 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:meshHeading | pubmed-meshheading:2037387-... | lld:pubmed |
| pubmed-article:2037387 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:2037387 | pubmed:articleTitle | A randomized study of on-line plasma perfusion over protein A-sepharose and 5-fluorouracil chemotherapy in patients with metastatic colorectal carcinoma. | lld:pubmed |
| pubmed-article:2037387 | pubmed:affiliation | Service d'Onco-Hématologie, C.H.U. Hautepierre, Strasbourg, France. | lld:pubmed |
| pubmed-article:2037387 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2037387 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2037387 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2037387 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2037387 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
